AVAC, IRMA and HIV PJA will be partnering in a three webinar series next week, starting on Monday, March 9, which will provide advocates with the chance to hear and discuss data—released last week at the Conference on Retroviruses and Opportunistic Infections (CROI)—in dialogue with researchers and other stakeholders.
The topics and times are below, including links to a host of resources to prepare for each webinar broadcast:
After FACTS: What's next for HIV prevention in women?
Monday, March 9, 11 a.m. ET // 10 a.m. CT // 9 a.m. MT // 8 a.m. PT
Click here to register.
This webinar will feature Helen Rees, principal investigator of the FACTS 001 microbicide trial of vaginal 1% tenofovir gel. FACTS 001, which released data at CROI, found no evidence of protection overall associated with the vaginal gel. Partners Demonstration Project, which reported data at the same meeting, found that serodiscordant couples using oral PrEP and/or ART had very low levels of HIV transmission. What do these and other data mean for women, including young women and adolescent girls? Join the call to share your thoughts and learn more!
Prepare for the webinar with these talks from CROI and excerpts from AVAC Report 2014/15:
- CROI Webcast: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women
- CROI Webcast: Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART
- Excerpts from AVAC Report on microbicides and PrEP
Follow the Money: Knowns and unknowns when it comes to cash transfers and financial incentives to improve health in people living with and/or at risk of HIV
Tuesday, March 10, 10 a.m. ET // 9 a.m. CT // 8 a.m. MT // 7 a.m. PT
Click here for more information and to register.
Demanding Clarity on PrEP: Understanding recent data on oral PrEP
Thursday, March 11, 12 p.m. ET // 11 a.m. CT // 10 a.m. MT // 9 a.m. PT
Click here for more information and to register.
